---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-213332"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2025-09-23T23:59:59+00:00"
generated_at: "2026-05-17T05:53:35.452993+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company

## Summary
- Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.
- Lead program targets 3M Americans with treatment-resistant depression (TRD); Phase 2 proof-of-concept trial expected to start 2026 with data in 2027.
- Company relaunches as innovation-driven neuropsychiatry firm, led by world-class team in neuropsychiatry, anesthesiology, and machine learning.
- Expanding pipeline beyond TRD; exploring therapies for other neuropsychiatric diseases with large unmet needs.

## SEC filing metadata
- accession: 0001193125-25-213332
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2025-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000119312525213332/0001193125-25-213332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000119312525213332/d51498d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-213332
- JSON: https://secwatch.observer/filing/0001193125-25-213332.json
- Plain text: https://secwatch.observer/filing/0001193125-25-213332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.